Treatment briefs.
Gilden
D
D
D018791:CD4 Lymphocyte Count; D002986:Clinical Trials as Topic; D016049:Didanosine / Q000009:adverse effects / Q000627:therapeutic use; D004345:Drug Industry; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000600:supply & distribution* / Q000627:therapeutic use; D006801:Humans; D019469:Indinavir; D019259:Lamivudine; D009414:Nerve Growth Factors / Q000627:therapeutic use*; D009422:Nervous System Diseases / Q000150:complications / Q000188:drug therapy*; D011725:Pyridines / Q000600:supply & distribution* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D018119:Stavudine / Q000009:adverse effects / Q000627:therapeutic use; D016047:Zalcitabine / Q000009:adverse effects / Q000600:supply & distribution* / Q000627:therapeutic use; D015215:Zidovudine / Q000627:therapeutic use
D017320:HIV Protease Inhibitors; D009414:Nerve Growth Factors; D011725:Pyridines; D011994:Recombinant Proteins; D019259:Lamivudine; D015215:Zidovudine; D019469:Indinavir; D016047:Zalcitabine; D018119:Stavudine; D016049:Didanosine